Actively Recruiting
Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer
Led by Anhui Provincial Hospital · Updated on 2024-06-25
36
Participants Needed
1
Research Sites
174 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Definitive concurrent chemoradiotherapy followed by durvalumab (Pacific protocol) has been the standard modality for stage III locally advanced non-small cell lung cancer. In spite of the median overall survival of 47.5 months, there still existed 38.5% and 6.9% patients who finally developed intra-thorax and extra-thorax recurrence respectively in long-term follow-up. The relatively low local control rate has been the bottleneck for further improvement of overall survival. Hypofraction radiotherapy has been validated to be able to increase the local control rate in two prospective trials. Therefore, this trial is designed to explore the safety and primary efficacy of hypofraction radiotherapy followed by immune checkpoint inhibitors for stage III locally advanced non-small cell lung cancer.
CONDITIONS
Official Title
Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18-70 years old
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Diagnosed with non-small cell lung cancer including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, or large-cell carcinoma
- Wild-type of driven genes
- Stage III confirmed by cranial MRI, chest CT, abdominal ultrasonography, bone scan or PET-CT
- Surgically unresectable or patient refuses surgery
- Signed informed consent
You will not qualify if you...
- Younger than 18 years or older than 70 years
- Eastern Cooperative Oncology Group (ECOG) performance status greater than 1
- Diagnosed with small-cell lung cancer or other neuroendocrine carcinomas including typical or atypical carcinoid, large-cell neuroendocrine carcinoma
- Mutant type of driven genes
- Not stage III confirmed by cranial MRI, chest CT, abdominal ultrasonography, bone scan or PET-CT
- Surgically resectable
- No signed informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Anhui Provicial Hospital
Hefei, Anhui, China
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here